Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes

What is Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes?

Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes is a CAR-T cell therapy engineered to target CD123-expressing tumor cells. The CAR incorporates CD28 co-stimulation and CD3 zeta signaling, with a truncated EGFR for detection and potential elimination. It is studied in acute myeloid leukemia, acute lymphoblastic leukemia, and other CD123-positive hematologic malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type

Cell therapy (CAR-T)

Targets

CD123 (IL3RA) (antigen)

Mechanism

Kills target cells, directed at CD123 (IL3RA)

Pathways

T-cell proliferation, antitumor cytotoxicity

Therapy area

Oncology

In trials of

MBIO

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaAdult Acute Lymphoblastic LeukemiaAdult Acute Myeloid Leukemia in RemissionBlastic Plasmacytoid Dendritic Cell NeoplasmEarly Relapse of Acute Myeloid LeukemiaInterleukin-3 Receptor Subunit Alpha PositiveLate Relapse of Acute Myeloid LeukemiaMinimal Residual DiseaseRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia

Other drugs acting on IL3RA

Sources

• NCI Thesaurus

Updated Oct 3, 2026.